Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer

Yoichi Nakanishi, Masayuki Kawasaki, Fen Bai, Koichi Takayama, Xin Hai Pei, Koichi Takano, Koji Inoue, Sin Ichi Osaki, Nobuyuki Hara, Chikako Kiyohara

研究成果: Contribution to journalArticle査読

36 被引用数 (Scopus)

抄録

To determine the predictive value of the expression of p53 and glutathione S-transferase-π (GST-π) with respect to chemotherapy response, immunostaining was performed on transbronchial biopsy specimens from previously untreated patients with non-small cell lung cancer. Of the 54 patients, 34 patients (63%) and 37 patients (69%) were positive for p53 and GST-π, respectively. The response rates in the p53-positive and p53-negative group were 15 and 45%, and those in GST-π-positive and GST-π-negative groups were 16 and 47%, respectively. A multiple logistic regression analysis revealed that positive immunostaining for GST-π was a significant risk factor for clinical chemotherapy resistance. The combination of these two markers was the most important independent factor in predicting a response to chemotherapy in multiple logistic regression analysis. Immunohistochemical expression of p53 and GST-π was independently related to clinical chemoresistance in patients with non-small cell lung cancer. Combined use of these two biomarkers may be a useful predictor of clinical chemoresistance.

本文言語英語
ページ(範囲)318-323
ページ数6
ジャーナルOncology
57
4
DOI
出版ステータス出版済み - 11 1999

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル